Dear all
I’ve finally receive the test report for my father, however
I am not sure to what extent are these results reliable, and what is the best
way to go from now on based on this report. I highly appreciate your advice. We
just started the Avestin (10 mg/kg) while being in our second cycle of Temodal
due to hug oedema (left temporal, biopsy-only, facing left eye ptosis few days
after the first cycle of Temodal)
Reports in the nutshell: MGMT methylated (36%), EGFR amplified,
IDH wildtype, Tert (Mutant for C250T, wildtype for C228T), 1P/19q (does not carry deletion of the genetic region 1p/19q), CMV negative (FFTP
tissue block)
1) How to decide when to stop Avastin, if ever?
2) Shall we reduce the Avastin dosage if we are going to stop
it after a short period?
3) Whether after stopping it, the temodal+ccnu can be still a
good option for us?
4) Shall we change temodal to CCNU now that we are facing
decline in his situation? Or is it better to wait until the end of 3rd
cycle, do the MRS and then decide?
5) Any cocktail
advice while we are starting Avestin? Maybe captopril and chloroquine (sadly, I just know about
EGFR and not the EGFRviii)
(his current Neutrophil
is 6600 and Platelets 89000, sleeping most of the time in the last 12 days, 20 minutes’
walk everyday)
Semi-Cocktail: metformin 500 (just to hopefully
prevent diabetes on dexa), CurcuMIND 2, Boswellia wokvel 3, acetazolamide 500, Keppra
750, valproate 500, Ranitidin 3, sulforaphane 1, Marrow plus (soon would be added
3), folic acid 1.
Report (the reason for quoting these in length is
mostly because I feel it could be helpful for other ppl in my situation to know
to what extant these tests are similar to what is done in other countries and maybe
it can help them saving more time and money. Sorry for the length, we can
delete it if it is inappropriate)
FFPT tissue block:
Positive for MGMT methylation (36.25% of methylation for
all 4 CpG sites):
Genomic DNA was obtained from tissue using the Qiagen kit. The
quality/quantity of the DNA was estimated in a Nanodrop spectrophotometer.
The MGMT methylation status was measured by Pyrosequencing
technology for 4 CpG islands within the methylated promoter region of the MGMT
encoding sequence.
Positive for EGFR amplification (approximately 11-fold
larger)
DNA was extracted using the QIAamp FFPE DNA kit. EGFR gene
amplification was analyzed by real-time PCR standard primers and probe using
Lightcycler 480 II instrument.
Comparing to the normal copy number of control gene, EGFR
gene was amplified in this sample.
Tert (Mutant for C250T, wildtype for C228T)
(QIAamp® DNA FFPE DNA Kit)
Allele Specific PCR was performed for amplification of TERT promoter mutations
(C228T, C250 T) by ABI Veriti instrument. Sequencing of PCR product were
performed via Pyromark Q96 instrument and analyzed to detect Polymorphism.
Wildtype for IDH1
(c.394-396 [R132H and variants])/ Wildtype for IDH2 (c.514-516 [R172K
and R140Q and variants])
DNA extracted by FFPE QIAGEN kit and a segment of DNA containing
IDH1 exon 2 and IDH2 exon 4 is amplified using ellele specific PCR primers and
Pyrosequencing data at codons 132, 140 and 172 respectively, is interpreted by
a pathologist.
CMV negative (FFTP tissue block)
DNA was extracted using the Qiagen DNA micro kit and
qualitative Real time PCR has been done using Taq-Man Probe assay to detect of
viral nucleic acid.
1P/19q (the assayed sample does not carry deletion of the
genetic region 1p/19q)
FISH analysis was performed on a section from a paraffin
embedded tissue block using differentially labeled fluorescent probes targeting
1p36/1q25 and 19p13/19q13.
The fluorescence in situ hybridization on the paraffin
tissue was positive for a co-deletion of 1p/19q. (???)FISh was performed
using probes for the target at 1p36 and 19q13 and control probes at 1q25 and
19p13.